PL-114-146 — Adding Zika Virus to the FDA Priority Review Voucher Program Act

Preamble

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, <<NOTE: Adding Zika Virus to the FDA Priority Review Voucher Program Act.>>

Section 1 — SHORT TITLE

This Act may be cited as the ``Adding Zika Virus to the FDA Priority Review Voucher Program Act''.

Section 2 — EXPANDING TROPICAL DISEASE PRODUCT PRIORITY REVIEW VOUCHER

PROGRAM TO ENCOURAGE TREATMENTS FOR ZIKA VIRUS DISEASE.

Section 524(a)(3) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360n(a)(3)) is amended-- (1) by redesignating subparagraph (R) as subparagraph (S); (2) in subparagraph (Q), by striking ``Filoviruses'' and inserting ``Filovirus Diseases''; and (3) by inserting after subparagraph (Q) the following: ``(R) Zika Virus Disease.''.

Approved April 19, 2016.

LEGISLATIVE HISTORY--S. 2512: ---------------------------------------------------------------------------

CONGRESSIONAL RECORD, Vol. 162 (2016): Mar. 17, considered and passed Senate. Apr. 12, considered and passed House.

<all>